0000950170-24-025101.txt : 20240304 0000950170-24-025101.hdr.sgml : 20240304 20240304182123 ACCESSION NUMBER: 0000950170-24-025101 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240304 DATE AS OF CHANGE: 20240304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gollob Jared CENTRAL INDEX KEY: 0001821198 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 24717125 MAIL ADDRESS: STREET 1: C/O KYMERA THERAPEUTICS, INC. STREET 2: 200 ARSENAL YARDS, SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 ownership.xml 4 X0508 4 2024-03-01 0001815442 Kymera Therapeutics, Inc. KYMR 0001821198 Gollob Jared C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 false true false false Chief Medical Officer false Common Stock 2024-03-01 4 A false 24375 0.00 A 99084 D Common Stock 2024-03-04 4 S false 2022 41.4135 D 97062 D Common Stock 2024-03-04 4 S false 1106 42.3924 D 95956 D Common Stock 2024-03-04 4 S false 216 43.2564 D 95740 D Stock Option (Right to Buy) 43.50 2024-03-01 4 A false 146250 0.00 A 2034-02-28 Common Stock 146250 146250 D Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.05 to $41.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $43.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.065 to $44.025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. /s/ Bruce Jacobs, as Attorney-in-Fact 2024-03-04